Figure 5.

Oncolytic activity of MV-NIS administered IT or IV in a subcutaneous LNCaP prostate cancer model. Mice (n = 5 per group) received a single intratumoral (IT) or intravenous (IV) dose of 1.5 × 10⁶ TCID₅₀ measles virus–sodium iodide symporter (MV-NIS) or six injections (IT or IV) of the virus at a total dose of 9 × 10⁶ TCID₅₀ or equivalent control regimens of UV-inactivated MV-NIS. All mice treated with six MV-NIS doses injected either IT or IV were alive by day 120 post-treatment initiation (these two curves completely overlap in a straight line) and survived longer as compared to animals treated with a single viral dose. Mice treated with a single IT or IV dose of MV-NIS still had significantly longer survival compared to the UV-inactivated controls (P < 0.05).